FDA Approves Eli Lilly Diabetes Drug

May 16, 2022

The US Food and Drug Administration (FDA) has given the green light to Eli Lilly’s new type II diabetes therapy Mounjaro. The injectable drug is hailed as a potential blockbuster for Lilly, which has seen its stocks jump by 50% in the past year. Clinical trial data showed that the drug reduced A1C levels in many patients, which indicates improved blood sugar control. The drug also had promising beneficial effects on obesity.

According to Matthew Herper of STAT News, “Obesity was common in the studies, and among patients who received the 15 mg dose the average weight loss was 15 pounds more than placebo when given without insulin and 29 pounds more than placebo when patients were receiving insulin. More recent weight loss data have shown promise in patients who are obese but not diabetic.”